You are here: Industry Insights > Insulin

News List

The Performance of the Two Insulin Companies on Volumn-based Procurement in the First Year Yefenghong/PharmaSources
March 01, 2023
Two leaders of insulin made in China, Tonghua Dongbao and Gan & Lee Pharmaceuticals, has announced their performance in 2022 respectively. As the first year of centralized procurement of insulin, two companies' performance both declined in 2022.
Research Progress of Glucose Sensitive Insulin Smart Drug Delivery System PharmaSources/Xiao Ni Sha
December 10, 2021
Diabetes is one of the major social health problems in the world. Subcutaneous injection of insulin is the traditional administration in the diabetes treatment, which is inconvenient and painful.
Global Diabetes Market Outlook Dr. Preet Pal S.B.
November 22, 2021
Diabetes is a well-known metabolic disorder, and the number of people living with it continues to rise. Although it is a segment of opportunity for pharmaceutical manufacturers, understanding it is complex.
Centralized procurement cuts insulin prices, benefits millions of diabetes patients www.gov.cn
April 22, 2023
China's diabetes patients now have access to high-quality and more affordable insulin products, as the country's drug bulk-buying program for insulin products has led to an average price cut of 48 percent.
Sartorius Completes Acquisition of Novasep's Chromatography Biz contractpharma
February 08, 2022
For the Bioprocess Solutions Division, the company now forecasts sales revenue growth of about 17 to 21 percent for 2022.
AG Nessel Launches Investigation into Excessive Insulin Prices, Intends to Challenge MSC Decisions Impacting Consumer Protection FirstWordPharma
January 28, 2022
Michigan Attorney General Dana Nessel launched an investigation into Eli Lilly this week - one of the three largest drug companies that manufactures nearly all the insulin in the United States.
'Artificial Pancreas' Can Help Kids With Type 1 Diabetes drugs.com
January 20, 2022
Having a child with type 1 diabetes can be a challenging health condition for parents to manage, but new research suggests an "artificial pancreas"...
FDA Approves Second Biosimilar Insulin Product, Rezvoglar (insulin glargine-aglr) AmericanPharmaceuticalReview
December 22, 2021
The Food and Drug Administration approved the second biosimilar insulin product, Eli Lilly’s Rezvoglar (insulin glargine-aglr). Rezvoglar (insulin glargine-aglr) is biosimilar to Lantus (insulin glargine).
Insulin Rx Fills Down During the Pandemic Drugs
November 08, 2021
There has been a considerable decrease in the average number of weekly insulin prescription fills during the COVID-19 pandemic, according to a research letter published online Nov. 3 in JAMA Network Open.
Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials drugs
August 25, 2021
Oramed Pharmaceuticals Inc. announced today that it has enrolled and randomized over 25% of the planned 450 patients for its Phase 3 ORA-D-013-2 trial of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page